Jeff Sevigny

TL;DR: In patients with prodromal or mild AD, one year of monthly intravenous infusions of aducanumab reduces brain Aβ in a dose- and time-dependent manner, accompanied by a slowing of clinical decline measured by Clinical Dementia Rating—Sum of Boxes and Mini Mental State Examination scores.

TL;DR: Aducanumab (BIIB037), a human monoclonal antibody selective for aggregated forms of amyloid beta, is being investigated as a disease‐modifying treatment for Alzheimer's disease.

TL;DR: This corrects the article to show that the method used to derive the H2O2 “spatially aggregating force” is based on a two-step process, not a single step, like in the previous version of this paper.

TL;DR: Amyloid PET GCA SUVr decreases 10mg pooled dose suggests target engagement and greater brain volume decreases in the MTM treatment groups was consistent with prior AD immunotherapy trials but the absence of treatment related differences in the small eAD study should be interpreted with caution.

TL;DR: In this article, the identification of biomarkers of combined genetic variants and imaging measurements, in predicting faster decline in cognitive measures and brain glucose metabolism in populations with Alzheimer's disease or those susceptible to developing Alzheimer's diseases, is presented.